Search clinical trials for: 0.40 mcg tiotropium solution

Total 637 results

Boehringer Ingelheim

Completed

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Healthy
Aurinia Pharmaceuticals Inc.

Completed

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)

Keratoconjunctivitis Sicca | Dry Eye Syndrome

United States
Boehringer Ingelheim

Completed

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Finland, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Ireland, Israel, Italy, Korea, Republic of, Latvia, ... and more
Boehringer Ingelheim

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Klinikum Ludwigshafen

Completed

A Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients

Cardiac Surgery | Elderly

Germany
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Germany, Italy, Switzerland, South Africa
Imperial College London
Boehringer Ingelheim

Completed

Airway Effects of Tiotropium in Patients With COPD

COPD | LUNG DISEASES, OBSTRUCTIVE

United Kingdom
B. Braun Melsungen AG

Completed

Comparison of HES 130 in Balanced and in Unbalanced Solution

Decreased and Nonspecific Blood Pressure Disorders and Shock

China
Kyushu University

Completed

PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Japan
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Canada, United States
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Asthma

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Germany, Guatemala, Hungary, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovakia, Ukraine
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma

Asthma

Argentina, Austria, Croatia, Estonia, Guatemala, Hungary, India, Italy, Korea, Republic of, Latvia, Poland, Slovakia
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Aclaris Therapeutics, Inc.

Terminated

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Mylan Pharma UK Ltd.

Completed

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

COPD

China
B. Braun Melsungen AG

Terminated

Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)

Renal Insufficiency

Germany
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
Pfizer

Completed

A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation

Healthy

Belgium
VivaVision Biotech, Inc

Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaucoma, Open-Angle

United States
Dompé Farmaceutici S.p.A
Dompé US

Completed

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis (DEFENDO)

Neurotrophic Keratitis

United States
INSYS Therapeutics Inc

Terminated

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Spasms, Infantile

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Marian Macsai, MD

Recruiting

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

Fuchs' Endothelial Dystrophy

United States
Alcon Research

Completed

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Dry Eye
Xiang'an Hospital of Xiamen University

Completed

NIR Fluorescent Molecular Probe for the Identification of Breast Tissue (NIR)

Breast Cancer

China
INSYS Therapeutics Inc

Completed

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Seizures

United States
PharmaEssentia

Completed

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Healthy Volunteers

Canada
Novartis Pharmaceuticals

Withdrawn

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control (INITIATE)

Chronic Obstructive Pulmonary Disease (COPD)
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Sunnybrook Health Sciences Centre

Completed

Half-normal Saline in Atrial Flutter Ablation

Atrial Flutter

Canada
Medical University of Vienna
Fresenius Kabi

Completed

Crystalloids Versus Colloids During Surgery (CC)

Postoperative Complications | Fluid Overload

Austria
B. Braun Ltd. Centre of Excellence Infection Control

Completed

The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds (Lavasept 2)

Wounds

Switzerland
Boehringer Ingelheim

Completed

Tiotropium Respimat Pharmacokinetic Study in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Finland, Germany, Netherlands
Ohio State University Comprehensive Cancer Center

Completed

Indocyanine Green Lymphangiography in Identifying Thoracic Duct During Neck Surgery

Neck Dissection | Radical Lymph Node Dissection

United States
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

COPD

Turkey
Boehringer Ingelheim

Completed

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Healthy

Germany
Boehringer Ingelheim

Completed

Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
University of Debrecen

Completed

The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies

Subarachnoid Hemorrhage

Hungary
Tanta University

Completed

Booster Dose of HCG for Unruptured Follicle in Non IVF/ICSI Cycles

LUF - Luteinised Unruptured Follicle Syndrome

Egypt
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Boehringer Ingelheim
Pfizer

Completed

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Asthma

Austria, Germany, Hungary, Slovenia
Neutec Ar-Ge San ve Tic A.Ş

Completed

Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD

COPD
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Fresenius Kabi
B. Braun Melsungen AG; European Society of Anaesthesiology and Intensive Care

Completed

Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery (PHOENICS)

Hypovolaemia Due to Acute Blood Loss

Spain, France, Netherlands, Germany, Poland, Belgium, Czechia, Croatia, Austria, Romania
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom

3

Subscribe